Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera
- 1 February 2009
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 77 (2) , 764-769
- https://doi.org/10.1128/iai.01191-08
Abstract
Complement factor H (fH), a molecule that downregulates complement activation, binds to Neisseria meningitidis and increases resistance to serum bactericidal activity. We investigated the species specificity of fH binding and the effect of human fH on downregulating rat ( relevant for animal models) and rabbit ( relevant for vaccine evaluation) complement activation. Binding to N. meningitidis was specific for human fH ( low for chimpanzee fH and not detected with fH from lower primates). The addition of human fH decreased rat and rabbit C3 deposition on the bacterial surface and decreased group C bactericidal titers measured with rabbit complement 10- to 60-fold in heat-inactivated sera from human vaccinees. Administration of human fH to infant rats challenged with group B strain H44/76 resulted in an fH dose-dependent increase in CFU/ml of bacteria in blood 8 h later (P < 0.02). At the highest fH dose, 50 mu g/rat, the geometric mean number of CFU per ml was higher than that in control animals (1,050 versus 43 [P < 0.005]). The data underscore the importance of binding of human fH for survival of N. meningitidis in vitro and in vivo. The species specificity of binding of human fH adds another mechanism toward our understanding of why N. meningitidis is strictly a human pathogen.This publication has 55 references indexed in Scilit:
- Vaccine-Induced Opsonophagocytic Immunity to Neisseria meningitidis Group BClinical and Vaccine Immunology, 2008
- Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd ImmunityThe Journal of Infectious Diseases, 2008
- Defining Targets for Complement Components C4b and C3b on the Pathogenic NeisseriaeInfection and Immunity, 2008
- Transgenic Mice Expressing Human Transferrin as a Model for Meningococcal InfectionInfection and Immunity, 2007
- Immunity to Neisseria meningitidis Group B in Adults despite Lack of Serum Bactericidal AntibodyClinical and Vaccine Immunology, 2007
- Immunogenicity and Safety of a Combination of Two Serogroup B Meningococcal Outer Membrane Vesicle VaccinesClinical and Vaccine Immunology, 2007
- Functional and Specific Antibody Responses in Adult Volunteers in New Zealand Who Were Given One of Two Different Meningococcal Serogroup B Outer Membrane Vesicle VaccinesClinical and Vaccine Immunology, 2007
- Priming for Immunologic Memory in Adults by Meningococcal Group C Conjugate VaccinationClinical and Vaccine Immunology, 2006
- Protection by Meningococcal Outer Membrane Protein PorA-Specific Antibodies and a Serogroup B Capsular Polysaccharide-Specific Antibody in Complement-Sufficient and C6-Deficient Infant RatsInfection and Immunity, 2006
- Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among childrenThe Journal of Pediatrics, 1996